Camurus AB (publ)
Camurus AB (publ), a biopharmaceutical company, develops and commercializes medicines for severe and chronic diseases in Europe, Africa, the Middle East, North America, and Asia. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence and chronic pain; and Brixadi to treat opioid use disorder. It also provides CAM2038 for the treatment of chronic pain; CAM2029… Read more
Market Cap & Net Worth: Camurus AB (publ) (CAMRF)
Camurus AB (publ) (OTCGREY:CAMRF) has a market capitalization of $3.58 Billion ($3.58 Billion) as of March 19, 2026. Listed on the OTCGREY stock exchange, this USA-based company holds position #4825 globally and #2957 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Camurus AB (publ)'s stock price $59.98 by its total outstanding shares 59608634 (59.61 Million).
Camurus AB (publ) Market Cap History: 2017 to 2025
Camurus AB (publ)'s market capitalization history from 2017 to 2025. Data shows growth from $11.89K to $3.58 Billion (465.51% CAGR).
Camurus AB (publ) Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Camurus AB (publ)'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1.81x
Camurus AB (publ)'s market cap is 1.81 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
7.90x
Camurus AB (publ)'s market cap is 7.90 times its annual earnings
0.11x
Higher than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $11.89K | $54.31 Million | -$190.57 Million | 0.00x | N/A |
| 2018 | $6.72K | $49.32 Million | -$234.68 Million | 0.00x | N/A |
| 2019 | $262.28K | $105.61 Million | -$289.87 Million | 0.00x | N/A |
| 2020 | $768.95 Million | $336.00 Million | -$167.26 Million | 2.29x | N/A |
| 2021 | $768.95 Million | $600.57 Million | -$90.45 Million | 1.28x | N/A |
| 2022 | $1.30 Billion | $956.34 Million | $55.55 Million | 1.36x | 23.40x |
| 2023 | $1.30 Billion | $1.72 Billion | $431.44 Million | 0.76x | 3.01x |
| 2024 | $3.39 Billion | $1.87 Billion | $428.39 Million | 1.81x | 7.90x |
Competitor Companies of CAMRF by Market Capitalization
Companies near Camurus AB (publ) in the global market cap rankings as of March 19, 2026.
Key companies related to Camurus AB (publ) by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Camurus AB (publ) Historical Marketcap From 2017 to 2025
Between 2017 and today, Camurus AB (publ)'s market cap moved from $11.89K to $ 3.58 Billion, with a yearly change of 465.51%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $3.58 Billion | +5.59% |
| 2024 | $3.39 Billion | +160.43% |
| 2023 | $1.30 Billion | 0.00% |
| 2022 | $1.30 Billion | +69.07% |
| 2021 | $768.95 Million | 0.00% |
| 2020 | $768.95 Million | +293081.82% |
| 2019 | $262.28K | +3803.23% |
| 2018 | $6.72K | -43.51% |
| 2017 | $11.89K | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Camurus AB (publ) was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $3.58 Billion USD |
| MoneyControl | $3.58 Billion USD |
| MarketWatch | $3.58 Billion USD |
| marketcap.company | $3.58 Billion USD |
| Reuters | $3.58 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.